Hepatitis C Diagnosis and Treatment Market at an All-Time High till 2022 Industry Forecast with F. Hoffmann-La Roche Ltd, BMS, Merck & Co., Etc Players by MRFR

Market Research Future published a research report on Global Hepatitis C Diagnosis and Treatment Market provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Hepatitis C Diagnosis & Treatment market

Global Hepatitis C Diagnosis and Treatment Market – Sketch

Hepatitis C is the inflammation of liver caused by infection by hepatitis C virus characterized by a host of symptoms such as yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay coloured stools etc. According to the World Health Organisation, hepatitis C affects between 130–150 million people globally every year claiming a toll of 700000 lives. Of those who recover about 15-20% develop liver cirrhosis or liver cancer.

The market for hepatitis C diagnosis & treatment is driven by factors such as increasing prevalence of liver cancer, rise in government subsidy and reimbursement especially in U.S., greater screening especially in developing nations, drug abuse and unsafe sex etc. On the other hand, the market constraining factors are self-imitating nature of the disease in a sizable number of patients, challenge of herbal treatment offered at negligible prices especially in developing regions, price war between companies such as between Gilead and Merck, rising urbanization and better sanitation etc.

According to Centres for Disease Control & Prevention, in U.S., liver cancer incidence is increasing at a rapid rate (2.3 % per year overall from 2003 – 2012), second only to thyroid cancer. Moreover, the rate of deaths due to liver cancer is increasing faster than for any other type of cancer. Furthermore, Hepatitis B and C are major contributing factors to liver cancer.

According to American Cancer Society, Worldwide, the most common risk factor for liver cancer is chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). These infections lead to cirrhosis of the liver and are responsible for making liver cancer the most common cancer globally.

Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/1569

Segments for Global Hepatitis C Diagnosis and Treatment Market

Global hepatitis C diagnosis & treatment market has been segmented on the basis of diagnostic tests which comprises of Enzyme Immunoassay (EIA), Chemiluminescence Immunoassay (CIA), Point-of-Care Rapid Immunoassays and Recombinant Immunoblot Assay (RIBA) and others.

Regional Analysis for Global Hepatitis C Diagnosis and Treatment Market

Depending on geographic region, Hepatitis C diagnosis & treatment market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally, Americas is the largest market for global Hepatitis C diagnosis and treatment with Europe in the second position. However, the developed regions market is stagnant and will continue to do so with Asia Pacific region particularly India and China rising fast. Asia pacific region is expected to be fastest growing region in hepatitis C diagnosis & treatment market. The African region is expected to be a laggard and will show at most a moderate rate of growth.

Key Players for Global Hepatitis C Diagnosis and Treatment Market

Some of the key players in this market are: F. Hoffmann-La Roche Ltd (Switzerland), BMS (U.S), Merck & Co., Inc (U.S), Vertex Pharmaceuticals Incorporated (U.S) and others.

Global Hepatitis C Diagnosis and Treatment Market-Competitive Analysis

Hoffmann-La Roche Ltd (Switzerland), BMS (U.S), Merck & Co., Inc (U.S), Vertex Pharmaceuticals Incorporated (U.S), Gilead sciences Inc (U.S.)., Abbvie Inc (U.S.), Johnson & Johnson (U.S.), Glaxosmithkline plc (U.K), Novartis AG (Switzerland), Bristol-Myers Squibb (U.S.) are some of the prominent players at the forefront of competition in the Global Hepatitis C Diagnosis and Treatment Market and are profiled in MRFR Analysis.

October, 2013 – Janssen (Parent organisation Johnson & Johnson Services, Inc.) acquired investigational NS5A Inhibitor for the treatment of Hepatitis C from GlaxoSmithKline. According to company reports, GSK2336805 is an investigational NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis.

October, 2013 – Bristol-Myers Squibb to presented range of new Hepatitis C data at the 2013 American Association for the Study of Liver Diseases (AASLD). According to company reports, Bristol-Myers Squibb’s hepatitis C includes compounds with different mechanisms of action, biologics as well as small molecule direct-acting antivirals. These compounds were being studied as part of multiple treatment regimens with the goal of increasing SVR rates across different patient types. 

Get Prime Discount on Report @ https://www.marketresearchfuture.com/check-discount/1569

Some Brief Table of Contents of Report

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/hepatitis-c-diagnosis-treatment-market-1569